MorphoSys (MOR)
(Delayed Data from NSDQ)
$18.55 USD
-0.25 (-1.33%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $18.61 +0.06 (0.32%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
MorphoSys AG Unsponsored ADR (MOR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$11.54 | $18.25 | $4.75 | -38.62% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for MorphoSys AG Unsponsored ADR comes to $11.54. The forecasts range from a low of $4.75 to a high of $18.25. The average price target represents a decline of 38.62% from the last closing price of $18.80.
Analyst Price Targets (5 )
Broker Rating
MorphoSys AG Unsponsored ADR currently has an average brokerage recommendation (ABR) of 2.31 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.31 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 25% and 12.5% of all recommendations. A month ago, Strong Buy made up 25%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 1 |
ABR | 2.31 | 2.31 | 2.31 | 2.31 | 2.61 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Hold |
3/14/2024 | SVB Securities | Andrew Berens | Hold | Hold |
3/14/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
2/7/2024 | UBS | Xian Deng | Strong Buy | Hold |
2/6/2024 | Not Identified | Not Identified | Strong Sell | Hold |
11/22/2023 | Goldman Sachs | Rajan Sharma | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.31 |
ABR (Last week) | 2.31 |
# of Recs in ABR | 8 |
Average Target Price | $11.54 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.54 |